Kathleen D. Scott is CFO at ARS Pharmaceuticals, Inc. (SPRY). They have made 3 open-market trades across 2 companies since 2022, most recently 2026-06-16.
CIK 0001794284
1 open-market purchase totalling $51K since 2022, against 2 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| SPRY | 22,542 | $90K |
| DRMA | 27,145 | $23K |
| Total | $113K |
Shares reported on the most recent Form 4, priced at the 2025-08-22 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| DRMA | SELL | 2026-06-16 | 2026-06-16 | $1.19 | $13 | +7.3% | +4.1% | -5.7% |
| SPRY | SELL · 10b5-1 | 2025-08-21 | 2025-08-22 | $15.00 | $188K | -20.6% | -27.3% | -50.0% |
| SPRY | SELL | 2025-05-20 | 2025-05-22 | $14.10 | $705K | -4.8% | +14.1% | +0.6% |
| SPRY | SELL · 10b5-1 | 2024-10-16 | 2024-10-17 | $16.00 | $200K | -5.8% | -14.4% | -25.4% |
| SPRY | SELL · 10b5-1 | 2024-08-20 | 2024-08-21 | $16.00 | $200K | -11.5% | +9.5% | +2.2% |
| SPRY | BUY | 2022-11-29 | 2022-12-01 | $6.24 | $51K | +25.0% | +27.8% | +37.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.